Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details)

v2.4.0.8
Summary of Significant Accounting Policies (Details) (USD $)
12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Segment
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Pharmaceutical [Member]
Segment
Dec. 31, 2013
Diagnostics [Member]
Segment
Dec. 31, 2013
Research and Development Expense [Member]
Dec. 31, 2012
Research and Development Expense [Member]
Dec. 31, 2011
Research and Development Expense [Member]
Dec. 31, 2013
Pharmsynthez [Member]
Apr. 30, 2013
Pharmsynthez [Member]
Dec. 31, 2013
Rxi Pharmaceuticals Corporation [Member]
Dec. 31, 2012
Rxi Pharmaceuticals Corporation [Member]
Dec. 31, 2011
Rxi Pharmaceuticals Corporation [Member]
Dec. 31, 2013
Neovasc [Member]
Dec. 31, 2012
Neovasc [Member]
Dec. 31, 2011
Neovasc [Member]
Dec. 31, 2013
Common Stock [Member]
Dec. 31, 2011
Common Stock [Member]
Oct. 31, 2011
Series D Preferred Stock [Member]
Dec. 31, 2011
Series D Preferred Stock [Member]
Common Stock [Member]
Dec. 31, 2013
Common Stock [Member]
Dec. 31, 2012
Common Stock [Member]
Dec. 31, 2011
Common Stock [Member]
Dec. 31, 2013
Minimum [Member]
Dec. 31, 2013
Maximum [Member]
Dec. 31, 2013
Software [Member]
Dec. 31, 2013
Machinery and Equipment [Member]
Minimum [Member]
Dec. 31, 2013
Machinery and Equipment [Member]
Maximum [Member]
Dec. 31, 2013
Furniture and Fixtures [Member]
Minimum [Member]
Dec. 31, 2013
Furniture and Fixtures [Member]
Maximum [Member]
Dec. 31, 2013
Buildings and Improvements [Member]
Minimum [Member]
Dec. 31, 2013
Buildings and Improvements [Member]
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]                                                                
Reduction of research and development expense from equity based compensation expense           $ (3,600,000) $ (2,000,000) $ (4,000,000)                                                
Maximum Number of Days Interest Bearing Instruments with Original Maturities to Consider as Cash Equivalent 90 days                                                              
Maximum Number of Days Interest Bearing Instruments with Remaining Maturities to Consider as Marketable Securities 90 days                                                              
Property, Plant and Equipment, Useful Life                                               5 years 10 years 3 years 5 years 8 years 5 years 10 years 10 years 40 years
Depreciation 4,100,000 1,800,000 400,000                                                          
Goodwill and intangible assets 1,100,000,000 200,000,000                                                            
Finite-Lived Intangible Asset, Useful Life                                               3 years 10 years              
Amortization of Intangible Assets 11,133,000 8,335,000 3,404,000                                                          
Finite-Lived Intangible Assets, Amortization Expense, 2014 11,000,000                                                              
Finite-Lived Intangible Assets, Amortization Expense, 2015 10,500,000                                                              
Finite-Lived Intangible Assets, Amortization Expense, 2016 9,600,000                                                              
Finite-Lived Intangible Assets, Amortization Expense, 2017 9,400,000                                                              
Finite-Lived Intangible Assets, Amortization Expense, 2018 7,100,000                                                              
Short Term Investments Maturities Period Minimum 90 days                                                              
Short Term Investments Maturities Period Maximum 1 year                                                              
Long Term Investments Maturities Period Minimum 1 year                                                              
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount                                         32,105,859 26,695,436 26,661,326                  
Series D preferred stock                                     80,654 940,141                        
Stock Issued During Period, Shares, Stock Options and Warrants Exercised 10,881,570 1,086,361                                                            
Stock Issued During Period, Shares, Stock Options and Warrants Exercised, Net of Shares Surrendered in Lieu of Cash Payment 10,732,745 1,084,982 3,348,394                                                          
Shares Surrendered in Lieu of Cash Payment 148,825 1,379                                                            
Exercise of Common Stock Warrants To Purchase Shares                                   3,702,497                            
Share Surrender In Lieu Of Cash Payment                                 354,103                              
Revenue from services 11,658,000 1,749,000 135,000                     200,000 1,400,000 100,000                                
Revenue from transfer of intellectual property 16,711,000 0 0                                                          
Revenue related to sale of intellectual property                     12,500,000 0 0                                      
Revenue related to our license agreements                 3,800,000                                              
Total deferred revenue related to other revenues 7,600,000 1,900,000               9,500,000                                            
Allowance for doubtful accounts receivable 1,885,000 474,000                                                            
Equity-based compensation expense for continuing operations $ 10,983,000 $ 5,131,000 $ 6,953,000                                                          
Number of reportable segments 2                                                              
Number of operating segments       2 2